Jan. 8 at 3:39 PM
$RLYB The more the data is 'delayed' from the Q4 2025 guidance, the more I think a deal is happening behind the scenes. Either a buyout/partner/or PIPE round of funding to continue RLYB116 into Phase 2 trials after good data. RM is still on the table as well. The fact that all of the original VCs are still hanging around is the most unique part. You don't typically see that in an RM situation (in
$VYNE situation most of them sold prior to RM annoucement). We could have something very big coming on our hands here.
